Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Receivables: 2023-2025

Historic Change in Receivables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $2.6 million.

  • Monte Rosa Therapeutics' Change in Receivables rose 129.14% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 925.82%. This contributed to the annual value of -$332,000 for FY2024, which is 82.50% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Change in Receivables of $2.6 million as of Q3 2025, which was up 170.14% from $961,000 recorded in Q2 2025.
  • Monte Rosa Therapeutics' Change in Receivables' 5-year high stood at $9.0 million during Q2 2024, with a 5-year trough of -$8.9 million in Q3 2024.
  • Over the past 3 years, Monte Rosa Therapeutics' median Change in Receivables value was $195,000 (recorded in 2023), while the average stood at $233,000.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Change in Receivables plummeted by 2,276.00% in 2024, and later spiked by 12,250.00% in 2025.
  • Monte Rosa Therapeutics' Change in Receivables (Quarterly) stood at $336,000 in 2023, then tumbled by 225.60% to -$422,000 in 2024, then surged by 129.14% to $2.6 million in 2025.
  • Its Change in Receivables stands at $2.6 million for Q3 2025, versus $961,000 for Q2 2025 and $1.2 million for Q1 2025.